← Leaderboards
Mark Alan Stidham
Trius Therapeutics, Inc.
$1,205,225
Attributed
$1,205,225
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $619.5K · FY2006–07$1M$750K$500K$250K$0
'06
'07
Funding mix
By agency
NIH$1,205,225 · 1
By mechanism
R43$1,205,225 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Analog”
- David Heimbrook · Leidos Biomedical Research, Inc.$196,589,777
- Constance Ann Benson · University Of California, San Diego$84,289,569
- Norman Wolmark · Nsabp Foundation, Inc.$51,982,954
- Robert Turner Schooley · University Of Colorado Denver$48,513,949
- Kenneth A Bloom · University Of Nebraska-Lincoln$46,979,168
- John Hobbs · Suny At Stony Brook$41,239,084
Research focus
AnalogAnthrax DiseaseAnti-Bacterial AgentsAntibioticsAntimicrobialAntisense TechnologyBacillus AnthracisBacillus Anthracis SporeBaseBinding (Molecular Function)Binding SitesBiochemicalBiodefenseBiologicalBreathingCell WallChemical PropertyCiprofloxacinClassCompatibleCrystallizationDesignDrug DesignAnabolism